WO2007047351A3 - Methods for treating hypertension in overweight and obese individuals - Google Patents

Methods for treating hypertension in overweight and obese individuals Download PDF

Info

Publication number
WO2007047351A3
WO2007047351A3 PCT/US2006/039862 US2006039862W WO2007047351A3 WO 2007047351 A3 WO2007047351 A3 WO 2007047351A3 US 2006039862 W US2006039862 W US 2006039862W WO 2007047351 A3 WO2007047351 A3 WO 2007047351A3
Authority
WO
WIPO (PCT)
Prior art keywords
ingredient
hypertension
methods
treating hypertension
agent
Prior art date
Application number
PCT/US2006/039862
Other languages
French (fr)
Other versions
WO2007047351A2 (en
Inventor
Kishore M Gadde
K Ranga R Krishnan
Anthony Mckinney
Original Assignee
Orexigen Therapeutics Inc
Kishore M Gadde
K Ranga R Krishnan
Anthony Mckinney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexigen Therapeutics Inc, Kishore M Gadde, K Ranga R Krishnan, Anthony Mckinney filed Critical Orexigen Therapeutics Inc
Publication of WO2007047351A2 publication Critical patent/WO2007047351A2/en
Publication of WO2007047351A3 publication Critical patent/WO2007047351A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are novel compositions for treating hypertension and conditions associated with hypertension comprising a first ingredient and a second ingredient, wherein the first ingredient comprises at least one anti-hypertensive agent and the second ingredient comprises at least one anti-obesity agent. Also disclosed are methods of treating hypertension and conditions associated with hypertension comprising administering a first ingredient and a second ingredient, wherein the first ingredient comprises at least one anti-hypertensive agent and the second ingredient comprises at least one anti-obesity agent. In various embodiments, the combinations act synergistically to alleviate symptoms and/or risk factors associated with hypertension. In preferred embodiments, the anti-obesity agent does not substantially affect blood pressure, and thereby decreases the risk and/or unpredictability associated with concurrent administration of the anti-hypertensive agent.
PCT/US2006/039862 2005-10-13 2006-10-13 Methods for treating hypertension in overweight and obese individuals WO2007047351A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72642505P 2005-10-13 2005-10-13
US60/726,425 2005-10-13

Publications (2)

Publication Number Publication Date
WO2007047351A2 WO2007047351A2 (en) 2007-04-26
WO2007047351A3 true WO2007047351A3 (en) 2007-11-01

Family

ID=37963079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/039862 WO2007047351A2 (en) 2005-10-13 2006-10-13 Methods for treating hypertension in overweight and obese individuals

Country Status (1)

Country Link
WO (1) WO2007047351A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9119850B2 (en) 2013-12-06 2015-09-01 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4343948B2 (en) 2003-04-29 2009-10-14 オレキシジェン・セラピューティクス・インコーポレーテッド Composition for affecting weight loss
EP2094259A1 (en) * 2006-12-15 2009-09-02 Novartis Ag Renin inhibitors for the prevention and treatment of hypertension in obese patients
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2011133212A1 (en) * 2010-04-20 2011-10-27 New York University Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
KR20150016405A (en) 2012-06-06 2015-02-11 오렉시젠 세러퓨틱스 인크. Methods of treating overweight and obesity
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364841A (en) * 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US20030135056A1 (en) * 2000-03-17 2003-07-17 Andersen Knud Erik Imidazole compounds
US20050137144A1 (en) * 2002-05-17 2005-06-23 Gadde Kishore M. Method for treating obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364841A (en) * 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US20030135056A1 (en) * 2000-03-17 2003-07-17 Andersen Knud Erik Imidazole compounds
US20050137144A1 (en) * 2002-05-17 2005-06-23 Gadde Kishore M. Method for treating obesity

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9107837B2 (en) 2006-06-05 2015-08-18 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9119850B2 (en) 2013-12-06 2015-09-01 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
WO2007047351A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007047351A3 (en) Methods for treating hypertension in overweight and obese individuals
WO2004110368A3 (en) Combination therapy for the treatment of hypertension
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
MX2008004734A (en) Leucine rich composition.
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
EP1521749B8 (en) PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES
WO2007117996A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2005123128A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2007092616A3 (en) Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
EP1935418A4 (en) Composition for relieving subjective symptoms of fatigue
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2008129396A3 (en) Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
WO2004110375A3 (en) Combination therapy for the treatment of diabetes
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
IL175220A (en) 3,5-substituted estrone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for inhibiting 17beta-hydroxysteroid dehydrogenase type i enzyme
WO2006124698A3 (en) Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
SG152257A1 (en) Topical preparation containing ambroxol
WO2005089803A3 (en) Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
WO2010045417A3 (en) Combination therapies for the treatment of obesity
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
EP2332526A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06825813

Country of ref document: EP

Kind code of ref document: A2